Under the terms of the agreement, BayPoint obtains exclusive, worldwide commercial rights to certain proteomic technologies as well as clinical biomarkers that predict therapeutic response for certain ovarian and breast cancers.
James Erickson, founder, president and CEO of BayPoint, said: “This strategic licensing agreement will further enable BayPoint to bring innovative personalized medicine products to the ovarian and breast cancer markets.
“The application of this technology also provides our pharmaceutical partners with new insights into how their drugs are working, in which cancers their drugs are most likely to be effective and how to rationally combine experimental drugs with approved therapeutics.”